Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip McCarthy

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|February 1, 2017
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Seminars in Oncology|February 14, 2002
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Transplantation and Cellular Therapy|July 5, 2026
System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced CostShernan G Holtan, Megan M Herr, Kanwal Mallhi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 23, 2005
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patientsHillard M Lazarus, Omer N Koc, Steven M Devine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant researchSteven Z Pavletic, Issa F Khouri, Michael Haagenson, et al.
Transplantation and Cellular Therapy|July 15, 2022
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 TrialQaiser Bashir, Taiga Nishihori, Marcelo C Pasquini, et al.
Haematologica|September 24, 2016
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesAndrew S Artz, Brent Logan, Xiaochun Zhu, et al.
Blood|July 2, 2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCTCorey Cutler, Brent Logan, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 17, 2002
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomesDaniel Weisdorf, Michael Bishop, Bernie Dharan, et al.
American Journal of Hematology|May 14, 2022
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAnita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|February 1, 2017
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Seminars in Oncology|February 14, 2002
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Transplantation and Cellular Therapy|July 5, 2026
System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced CostShernan G Holtan, Megan M Herr, Kanwal Mallhi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 23, 2005
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patientsHillard M Lazarus, Omer N Koc, Steven M Devine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant researchSteven Z Pavletic, Issa F Khouri, Michael Haagenson, et al.
Transplantation and Cellular Therapy|July 15, 2022
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 TrialQaiser Bashir, Taiga Nishihori, Marcelo C Pasquini, et al.
Haematologica|September 24, 2016
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesAndrew S Artz, Brent Logan, Xiaochun Zhu, et al.
Blood|July 2, 2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCTCorey Cutler, Brent Logan, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 17, 2002
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomesDaniel Weisdorf, Michael Bishop, Bernie Dharan, et al.
American Journal of Hematology|May 14, 2022
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAnita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, et al.
Pageof 6